Physician profile
Kara Prussing
NPI 1235662800
$2,894.53
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $856 · 2023: $1,599 · 2024: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,038.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $619.06 | 2022-2024 | |
| Alkermes, INC. | $482.68 | 2022-2024 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $255.51 | 2022-2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $243.18 | 2022-2024 | Trintellix |
| Axsome Therapeutics, INC. | $223.86 | 2022-2024 | Auvelity |
| Lundbeck LLC | $190.12 | 2022-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $176.23 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $141.87 | 2022-2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $111.73 | 2023-2024 | Jornay Pm |
| Corium, LLC | $84.16 | 2022-2023 | Azstarys |
| Neurocrine Biosciences, INC. | $73.63 | 2022-2023 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $57.79 | 2022-2023 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $52.30 | 2022-2023 | Austedo |
| Bausch Health US, LLC | $50.70 | 2022-2024 | Aplenzin |
| Idorsia Pharmaceuticals US INC | $49.65 | 2022-2023 | Quviviq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $41.23 | 2022-2024 | Dyanavel Xr |
| Biogen, INC. | $40.83 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Prussing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.